GB Patent

GB2462611A — Pharmaceutical composition comprising tetrabenazine

Assigned to Valeant Laboratories International Bermuda SRL · Expires 2010-02-17 · 16y expired

What this patent protects

A controlled release pharmaceutical composition in unit dosage form comprising tetrabenazine as the sole therapeutic agent and a release-retarding agent. The composition has a long half-life of some 13-15 hours. The release-retardig agent is a cellulose derivative such as hydroxy…

USPTO Abstract

A controlled release pharmaceutical composition in unit dosage form comprising tetrabenazine as the sole therapeutic agent and a release-retarding agent. The composition has a long half-life of some 13-15 hours. The release-retardig agent is a cellulose derivative such as hydroxypropylmethyl cellulose (HPMC) or hydroxypropyl cellulose (HPC).

Drugs covered by this patent

Patent Metadata

Patent number
GB2462611A
Jurisdiction
GB
Classification
Expires
2010-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Valeant Laboratories International Bermuda SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.